# **EXHIBIT B**

# HALE AND DORR LLP



#### haledorr.com

THE WILLARD OFFICE BUILDING 1455 PENNSYLVANIA AVENUE N.W. • WASHINGTON, D.C. 20004-1008 202-942-8400 • FAX 202-942-8484

Total Number of Pages: 11

Fax / Phone:

To:

Luisa Bigornia

BioMarin Pharmaceuticals Inc.

(415) 382-3511 / (415) 884-6709

Prom: Maria L. Maebius

202-942-8452

Date: August 4, 2003

Note:

Please find attached declarations for execution

12:50 pm eve AUG 4 - 2003

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call 202-942-8333, and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call 202-942-8333. Thank you.

Client Matter Number: 104385.140

Return To:

Jacquelyn Price

Transmitted by:

BOSTON

LONDON MUNICH NEW YORK

OXFORD PRINCETON

HOTDHIEZAW

# HALE AND DORR LLD

#### haledorr.com

THB WILLARD OFFICE BUILDING
1455 PENNSYLVANIA AVENUE, N.W. • WASHINGTON, D.C. 20004-1008
202-942-8400 • FAX 202-942-8484

MARIA L. MAEBIUS

202-942-8452 maria machins@haledor.com

August 4, 2003

### VIA FACSIMILE

Dr. Luisa Bigornia BioMarin Pharmaceuticals Inc. 371 Bel Marin Keys Boulevard, Suite 210 Novato, CA 94949

Re:

U.S. Patent Application No. 08/722,659

Title: Use of Heparinase to Decrease Inflammatory Response

Inventors: Bennett et al.; Filed: September 27, 1996

Our Reference No.: 104385.140

#### Dear Luisa:

Further to our letter of March 20, 2003, we have received a Board of Patent Appeals and Interferences Docketing Notice from the U.S. Patent and Trademark Office. The above referenced application has been assigned Appeal No. 2003-1678.

In addition, attached are the four Declarations under 37 CFR 1.132 for the execution by Dominique Fink, Elizabeth Cauchon, Brigette Grouix, and Ariane Hsia for your review. Please let me know if you need assistance locating these inventors.

If you have any questions, please do not hesitate to contact us.

Very truly yours,

Maria L. Maebius

MLM:dal Enclosure

cc: Hollie Baker

RESTON



United States Patent and Trademaric Office

Chaire Special dis Computers for Island States Parish and Tradegraph Chrice
Washington DC 20231

WWW.uspto.gov

HOLLIE L. BAKER HALE & DORR LLP. 60 STATE STREET BOSTON, MA 02109

Paper No. 199 Appeal No. 2003-1678

Appellant BENNETT, D. CLARK

Application: 08/722,659

MAILED
JUN 2 7 2003
PAI & TM. OFFICE
ROARD OF PATENT APPEALS
AND INTERFERENCES

# Board of Patent Appeals and Interferences Docketing Notice

Application 08/722,659 was received from the Technology Center at the Board on June 11, 2003 and has been assigned Appeal No: 2003-1678.

A review of the file indicates that the following documents have been filed by appellant:

Appeal Brief filed on:

November 4, 2002

Reply Brief filed on:

March 13, 2003

Request for Hearing filed on: None

In all future communications regarding this appeal, please include both the application number and the appeal number.

The mailing address for the Board is:

BOARD OF PATENT APPEALS AND INTERFERENCES UNITED STATES PATENT AND TRADEMARK OFFICE P.O. BOX 1450 ALEXANDRIA, VIRGINIA 22313-1450

The facsimile number of the Board is 703-308-7952. Because of the heightened security in the Washington D.C. area, facsimile communications are recommended. Telephone inquiries can be made by calling 703-308-9797 and should be directed to a Program and Resource Administrator.

By order of the Board of Patent Appeals and Interferences

HALE & DORR DOCKETING

RE: 10955. 140 US2

Action Date: 7.13.03

Action to be Taken: DD 7

Docketed By DIMD On: 7.6.03

Attorney Docket No. 104385.140

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

111 16 Y	Application of:	)
	BENNETT et al.	) Group Art Unit: 1644
Serial	No.: 08/722,659	) Examiner: A. DeCloux
Filed:	September 27, 1996	) )
For:	USE OF HEPARINASE TO DECRE	) ASE INFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

### DECLARATION UNDER 37 C.F.R. § 1.132 OF ARIANE HSIA

- I, Ariane Hsia, do hereby declare that:
- 1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
  - 4. The undersigned declares further that all statements made herein of my own

Signed at		
this _ day of	. 2003.	Ariane Hsia

Attorney Docket No. 104385.140

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:  BENNETT et al.	) Group Art Unit: 1644
	) Gloup Art Omt: 1644 )
Serial No.: 08/722,659	) Examiner: A. DeCloux
Filed: September 27, 1996	<b>;</b>
For: USE OF HEPARINASE TO DECR	) EASE INFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

### DECLARATION UNDER 37 C.F.R. § 1.132 OF ELIZABETH CAUCHON

- I, Elizabeth Cauchon, do hereby declare that:
- 1. I am a joint inventor of the subject matter claimed in the above-identified application, along with Dominique Fink, Brigette Grouix, Ariane Hsia, Joseph Zimmermann, D. Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
  - 4. The undersigned declares further that all statements made herein of my own

Signed at		
this day of	2003	Elizabeth Cauchon

Attorney Docket No. 104385.140

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applic	ation of:	)
BEN	INETT et al.	) Group Art Unit: 1644
		)
Serial No.:	08/722,659	) Examiner: A. DeCloux
		)
Filed: Septe	ember 27, 1996	)
	•	)
For: USE	OF HEPARINASE TO DECRI	EASE INFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

### DECLARATION UNDER 37 C.F.R. § 1.132 OF DOMINIQUE FINK

- I, Dominique Fink, do hereby declare that:
- I am a joint inventor of the subject matter claimed in the above-identified
   application, along with Elizabeth Cauchon, Brigette Grouix, Ariane Hsia, Joseph Zimmermann,
   D. Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
  - 4. The undersigned declares further that all statements made herein of my own

BIUMAKIN MERRILL DMS **4**016 **4**009

Signed at			
			Dominique Fink
thic	day of	2003	

Attorney Docket No. 104385.140

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

un re A	Application of:	)	
	BENNETT et al.	)	Group Art Unit: 1644
a	27	)	
Serial No.: 08/722,659		)	Examiner: A. DeCloux
T21 - J.	Santa-1. 07 1006	)	
rileu:	September 27, 1996	)	
For:	TICE OF HERADINA OF TO PROP	)	
1 01.	USE OF HEPARINASE TO DECR	FASE II	NFLAMMATORY RESPONSE

Commissioner for Patents Washington, D.C. 20231

### DECLARATION UNDER 37 C.F.R. § 1.132 <u>OF BRIGETTE GROUIX</u>

- I, Brigette Grouix, do hereby declare that:
- I am a joint inventor of the subject matter claimed in the above-identified application, along with Elizabeth Cauchon, Dominique Fink, Ariane Hsia, Joseph Zimmermann,
   Clark Bennett, and Pamela Danagher.
- 2. I am informed and believe that U.S. Patent No. 5,997,863 ("the'863 patent"), a copy of which is attached as Exhibit A, has been cited against the claims of the above-identified application. In particular, I am informed and believe that Example 8 found at col. 17, line 63-col. 18, line 29 has been cited against the above-captioned application in a prior art rejection.
- 3. While I am a co-inventor of the above-captioned application, I did not make an inventive contribution to the subject matter recited in paragraph 2. In particular, I was not involved in the animal model work described in Example 8 involving the local administration of heparinase to enhance revascularization, described generally at col. 17, line 63-col. 18, line 29.
  - 4. The undersigned declares further that all statements made herein of my own

Signed at			
this day of	2002	•	Brigette Grouix